Meanwhile, the PD-1/PD-L1 pathway is one of the inhibitory receptors of the immune system that is exploited by cancer cells to evade immune surveillance; blocking this pathway leads to a cytotoxic antitumor response.7 TMB and PD-1/PD-L1 expression are routinely assessed and used to guide therapeutic decisions in solid malignancies. This evidence concerns the gene CD274 and cancer.